基于重复测量的不同用药方案和血压水平高血压患者报告结局比较

唐顺定, 张雯, 邓丽, 宋莹, 王涵, 张晓磬, 张茹

PDF(524 KB)
PDF(524 KB)
重庆医科大学学报 ›› 2024, Vol. 49 ›› Issue (03) : 329-334. DOI: 10.13406/j.cnki.cyxb.003442
临床研究

基于重复测量的不同用药方案和血压水平高血压患者报告结局比较

作者信息 +

Repeated measures-based comparison of patient-reported outcomes for patients with hypertension having different medication regimens and blood pressure levels

Author information +
History +

摘要

目的 基于患者报告的临床结局(patient reported outcomes,PRO)比较不同血压水平的高血压患者对于不同用药方案的治疗效果,为临床医生选择用药方案提供线索。 方法 对正在服用降压药物的625例社区高血压患者进行PRO基线测量,并每3个月测量1次,共重复测量3次。采用重复测量方差分析法,分析比较不同时间点2种用药方案(单一用药、联合用药)和3种血压水平(1级高血压、2级高血压、3级高血压)构成的6种组合的PRO差异。 结果 重复测量方差分析结果显示,不同用药方案、血压水平的高血压患者在3次重复测量后PRO得分产生不同程度的波动。单一用药的1级高血压患者,身体健康、心理健康、社会健康、精神/信仰健康、特异模块领域的PRO得分均波动下降;单一用药的2级、3级高血压患者,心理健康、社会健康、精神/信仰健康领域得分均波动上升。联合用药的1级、2级、3级高血压患者身体健康领域PRO得分没有差异。联合用药的2级高血压患者心理健康领域得分呈下降趋势。联合用药的3级高血压患者社会健康得分呈波动上升趋势。联合用药的1级高血压精神/信仰健康得分呈波动下降趋势,2级高血压精神/信仰健康得分呈上升趋势。联合用药的2级高血压患者特异模块得分呈下降趋势。从量表总分看,1级高血压患者,无论是单一用药还是联合用药PRO得分均下降,2级高血压和3级高血压患者使用单一用药和联合用药时PRO得分均呈波动上升趋势。 结论 不同血压水平的高血压患者对于单一用药和联合用药治疗后PRO得分不同,临床医生在选择用药方案时可参考患者的PRO。

Abstract

Objective To compare the therapeutic effects of different medication regimens in patients with hypertension with different blood pressure levels based on patient reported outcomes(PROs),and to provide a reference for clinicians to choose medication regimens. Methods A total of 625 community patients with hypertension who were taking antihypertensive medications underwent a baseline PRO measure and three repeated-measures of PRO(once every three months). Repeated-measures analysis of variance (ANOVA) was used to compare the PRO of six combinations generated with two medication regimens(single medications and combined medications) and three blood pressure levels(grade-1 hypertension,grade-2 hypertension,and grade-3 hypertension) at different time points. Results Repeated-measures ANOVA results showed that patients with hypertension having different medication regimens and blood pressure levels had varying degrees of fluctuations in PRO scores across three repeated measures. For patients with grade-1 hypertension on single medications,PRO scores in physical health,mental health,social health,spiritual/faith-related health,and the specific module fluctuated downward. For both patients with grade-2 hypertension and those with grade-3 hypertension on single medications,the scores in mental health,social health,and spiritual/faith-related health fluctuated upward. There were no significant differences in PRO scores in physical health among grade-1,-2,and -3 hypertensive patients on combined medications. There was a downward trend in mental health-related PRO score in patients with grade-2 hypertension on combined medications. The PRO score in social health showed a fluctuating upward trend in patients with grade-3 hypertension on combined medications. For patients with grade-1 hypertension and those with grade-2 hypertension on combined medications,the PRO score in spiritual/faith-related health fluctuated downward and upward,respectively. There was a downward trend in the specific module score of patients with grade-2 hypertension on combined medications. The total PRO score declined in patients with grade-1 hypertension and fluctuated upward in patients with grade-2 and grade-3 hypertension,regardless of single or combined medications. Conclusion Patients with different grades of hypertension have varying PRO scores with single and combined medications,and clinicians can refer to patients’ PROs when choosing medication regimens.

关键词

高血压 / 患者报告的临床结局 / 用药方案

Key words

hypertension / patient-reported outcome / medication regimen

中图分类号

R544.1

引用本文

导出引用
唐顺定 , 张雯 , 邓丽 , . 基于重复测量的不同用药方案和血压水平高血压患者报告结局比较. 重庆医科大学学报. 2024, 49(03): 329-334 https://doi.org/10.13406/j.cnki.cyxb.003442
Tang Shunding, Zhang Wen, Deng Li, et al. Repeated measures-based comparison of patient-reported outcomes for patients with hypertension having different medication regimens and blood pressure levels[J]. Journal of Chongqing Medical University. 2024, 49(03): 329-334 https://doi.org/10.13406/j.cnki.cyxb.003442

参考文献

1
《中国心血管健康与疾病报告2021》编写组. 《中国心血管健康与疾病报告2021》概述[J]. 中国心血管病研究202220(7):577-596.
The Writing Committee of the Report on Cardiovascular Health and Diseases in China 2021. Key points of Report on Cardiovascular Health and Diseases in China 2021[J]. Chin J Cardiovasc Res,2022,20(7):577-596.
2
Wang ZW Chen Z Zhang LF,et al. Status of hypertension in China:results from the China hypertension survey,2012-2015[J]. Circulation2018137(22):2344-2356.
3
隆莉芝,袁 玲. 患者报告结局的应用近况及思考[J]. 中国全科医学202023(32):4120-4127.
Long LZ Yuan L. The application and consideration of patient-reported outcomes[J]. Chin Gen Pract202023(32):4120-4127.
4
Department of Health and Human Services FDA Center for Drug Evaluation and Research US,Department of Health and Human Services FDA Center for Biologics Evaluation and Research US,Department of Health and Human Services FDA Center for Devices and Radiological Health US .Guidance for industry:patient-reported outcome measures:use in medical product development to support labeling claims:draft guidance[J]. Health Qual Life Outcomes20064:79.
5
周 慧,林 颖,周国进,等. 《将患者报告结局纳入临床研究的伦理考量:PRO伦理指南》解读[J]. 中国全科医学202326(4):395-400.
Zhou H Lin Y Zhou GJ,et al. Interpretation of ethical considerations for the inclusion of patient-reported outcomes in clinical research(the PRO ethics guidelines)[J]. Chin Gen Pract202326(4):395-400.
6
Quittner AL Nicolais CJ Saez-Flores E. Integrating patient-reported outcomes into research and clinical practice[M]//Kendig’s Disorders of the Respiratory Tract in Children. Amsterdam:Elsevier,2019:231-240.
7
《中国高血压防治指南》修订委员会. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志201924(1):24-56.
Writing Group of Chinese Guidelines for the Management of Hypertension. 2018 Chinese guidelines for the management of hypertension[J]. Chin J Cardiovasc Med201924(1):24-56.
8
国家卫生计生委合理用药专家委员会,中国医师协会高血压专业委员会. 高血压合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版),20179(7):28-126.
Expert Committee on Rational Use of Medicines of the National Health and Family Planning Commission,Hypertension Specialized Committee of China Medical Doctors Association. Guidelines for rational drug use in hypertension (2nd edition)[J]. Chin J Front Med Sci Electron Version20179(7):28-126.
9
Paudel N Shrestha S Marasine NR,et al. Impact of hospital pharmacist-delivered individualised pharmaceutical service intervention on clinical and patient-reported outcomes in patients with hypertension:a randomised controlled trial[J]. Eur J Hosp Pharm202330(6):316-321.
10
史 钊,窦 蕾,李顺平. 国内外患者报告结局的应用现状与研究进展[J]. 中国全科医学202326(4):401-408.
Shi Z Dou L Li SP. Patient-reported outcome:recent advances in applications and research at home and abroad[J]. Chin Gen Pract202326(4):401-408.
11
曹 阳,余小萍. PRO 量表国内外研究近况[J]. 中医杂志201455(8):710-714.
Cao Y Yu XP. Research status of PRO scale at home and abroad[J]. J Tradit Chin Med201455(8):710-714.
12
彭丽霞,张 勇. 高血压患者报告结局的研究现状[J]. 保健医学研究与实践202118(1):100-104.
Peng LX Zhang Y. Research status of reporting outcomes in patients with hypertension[J]. Health Med Res Pract202118(1):100-104.
13
Masyuko S Ngongo CJ Smith C,et al. Patient-reported outcomes for diabetes and hypertension care in low- and middle-income countries:a scoping review[J]. PLoS One202116(1):e0245269.

基金

云南省科技厅基础研究计划资助项目(202101AY;070001-221)
云南省科技厅—昆明医科大学基础研究联合专项资助项目(202401AY070001-067)
云南省科技厅—昆明医科大学应用基础研究联合专项资助项目(2019FE001-181)

评论

PDF(524 KB)

Accesses

Citation

Detail

段落导航
相关文章

/